Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolerability of Mirikizumab SC Formulations in Healthy Volunteers
NCT03748940Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2018
- Primary completion
- Jun 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of mirikizumab in ulcerative colitis (UC), Crohn's disease and psoriasis (5 arms), sponsored by Eli Lilly and Company. Primary endpoint: Visual Analog Scale Pain Score. Started Oct 2018; status: completed.
02
Drugs
mirikizumab
03
Conditions
ulcerative colitis (UC)Crohn's diseasepsoriasis
Beyond the preview
Go deeper on NCT03748940.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03748940.